Journal September 25, 2026 5 min read

How Does Neuroinflammation Work?

Neuroinflammation is a multicellular response of the central nervous system, driven by innate immune signalling, metabolic stress and glial activation. This page outlines the mechanistic evidence, including where finding

peptides-pro Editorial

Neuroinflammation is the innate immune response of the central nervous system (CNS), characterised by activation of microglia and astrocytes, release of cytokines and chemokines, and disruption of the blood–brain barrier. It is not a single molecular entity but a process; the term encompasses signalling through pattern-recognition receptors, inflammasome assembly, and metabolic reprogramming of glial cells. In the research literature, neuroinflammation is studied in models of traumatic brain injury (TBI), neurodegenerative disease, ischaemia, and metabolic disorders. The evidence base includes in vitro cell culture, animal models, and human clinical trials, with the strength of inference varying accordingly.

The mechanistic work described below centres on the NLRP3 inflammasome and its regulation by adenosine monophosphate-activated protein kinase (AMPK), a pathway that links cellular energy status to inflammatory cytokine production.

Research Studies

AMPK activators and NLRP3 inflammasome-mediated neuroinflammation in a rat weight-drop model of TBI

A study in Sprague-Dawley rats used a weight-drop model of traumatic brain injury to investigate whether AMPK activation suppresses NLRP3 inflammasome-mediated neuroinflammation [3]. The AMPK activators tested included metformin, quercetin, resveratrol, cinnamaldehyde, and berberine. The study reported that AMPK activation was associated with suppression of NLRP3 inflammasome activity and reduced neuroinflammatory markers in this animal model [3]. This finding is animal-only; it does not establish efficacy or safety in humans.

Magnesium sulphate and NMDA receptor blockade in neonatal asphyxia

In term neonates with birth asphyxia, a randomised controlled trial is evaluating adjuvant intravenous magnesium sulphate (250 mg/kg within 6 hours of birth) for its potential to reduce hospital stay and improve short-term outcomes [1]. The proposed mechanism is blockade of NMDA receptors, which limits cellular calcium influx and downstream neuroinflammation [1]. This trial is ongoing; no results are available in the evidence provided.

Tauroursodeoxycholate and liver-targeted therapy for diabetic macular edema

Diabetic macular edema is a complication of diabetic retinopathy in which systemic inflammation and hepatic metabolic dysfunction are implicated in the neuroinflammation and vascular dysfunction observed [2]. A clinical trial is investigating Tauroursodeoxycholate (a bile acid) and modified traditional Chinese medicine as liver-targeted interventions [2]. The rationale is that addressing hepatic metabolism may indirectly modulate neuroinflammation [2]. This trial is ongoing; no outcomes are reported in the evidence provided.

Oxiracetam and cognitive impairment: a narrative review

A narrative review evaluated the mechanistic basis, clinical efficacy, and safety of oxiracetam for cognitive dysfunction across neurological disorders [6]. The review synthesised preclinical and clinical literature, including effects on cholinergic signalling [6]. The evidence is mixed and the review does not provide a definitive conclusion on neuroinflammation specifically.

NMNAT-1 and NAD+ homeostasis in neuroprotection and aging

Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyses the final step in NAD+ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family [7]. Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, and direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited axonal degeneration [7]. The causal node and limiting compartment differ across tissues and disease states [7]. This work links metabolic cofactor homeostasis to neuronal maintenance and inflammation, but the evidence for neuroinflammation per se is indirect.

Coenzyme Q10 and sevoflurane-induced neuroinflammation in mouse hippocampal neurons

A study in mouse hippocampal neurons reported that coenzyme Q10 alleviates sevoflurane-induced neuroinflammation by regulating apolipoprotein E and phosphorylated tau [8]. However, a corrigendum has been issued: the authors acknowledged a methodological error in which an inappropriate antibody was used to probe for tau paired helical filaments, affecting the western blot results [8]. This finding is animal-only and the reliability of the reported data is compromised by the corrigendum.

Natural medicines for Alzheimer's disease: bibliometric analysis and narrative review

A bibliometric analysis and narrative review mapped research trends and mechanistic insights for natural medicines in Alzheimer's disease [4]. The analysis covered publications from 2001 to 2025 and examined representative mechanistic evidence [4]. The review does not focus exclusively on neuroinflammation but provides a landscape of the field.

Nutritional paradox in uremia: sensitise-then-feed framework

A perspective on protein-energy wasting in advanced chronic kidney disease proposed a 'sensitise-then-feed' framework to address anabolic resistance [5]. While not directly about neuroinflammation, it discusses systemic inflammation and metabolic dysfunction that may intersect with CNS inflammation [5]. This is a conceptual model, not primary data on neuroinflammation.

Reference-only findings

Several additional studies inform the broader picture of neuroinflammation mechanisms. A review of astrocytic failure in Parkinson's disease positions astrocyte dysfunction as a central driver of pathogenesis, extending the concept of neuroinflammation beyond microglia [9]. Another study reports that bilirubin impacts microglial lipophagy via the AMPK-mTOR signalling pathway, linking bilirubin homeostasis to neuroinflammation in bilirubin encephalopathy [10]. A third study triangulates the neuroprotective mechanisms of pterostilbene in hyperhomocysteinemia-induced cognitive impairment using in silico, proteomics, and experimental validation [11]. Finally, a study found that TRIM28 SUMOylates IRF3 in astrocytes to drive neutrophil infiltration and ischemic cerebral injury, highlighting crosstalk between the nervous and immune systems [12]. These findings are reported here as facts from the respective papers; they are not the focus of this page.

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.